Clinical data
Synonyms 5,6-Dihydro-2-methyl-4-[4-nitro-3-(trifluoromethyl)phenyl]-2H-1,2,4-oxadiazin-3-(4H)-one[1]
Drug class Nonsteroidal antiandrogen
PubChem CID
Chemical and physical data
Formula C11H10F3N3O4
Molar mass 305.213 g/mol
3D model (JSmol)

RU-22930 is a nonsteroidal antiandrogen (NSAA) related to the NSAAs flutamide and nilutamide (RU-23908) and was developed by Roussel Uclaf but was never marketed.[2][3] It is a selective antagonist of the androgen receptor and consequently has progonadotropic effects by increasing gonadotropin and testosterone levels via disinhibition of the hypothalamic-pituitary-gonadal axis.[2] Unlike flutamide and nilutamide, the drug is said to be short-acting and inactive by injection, but it has been found to be active topically in animals, and hence could be useful for the treatment of androgen-dependent skin conditions.[2][4]

See also


  2. 1 2 3 Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacol. Ther. 24 (3): 367–400. PMID 6205409.
  3. Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr. Med. Chem. 7 (2): 211–47. PMID 10637363.
  4. Thomson, D. S. (1989). "Pharmacology of Anti-androgens in the Skin". 87 / 2: 483–493. doi:10.1007/978-3-642-74054-1_36. ISSN 0171-2004.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.